NAMI-A

Research use only, not for human use.

NAMI-A, a ruthenium-based compound, selectively targets tumor metastasis by inhibiting cancer cell adhesion and migration.

NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases,inhibits the adhesion and migration.In vitro:NAMI-A can significantly affect tumor cells with metastatic ability.The half lifetime of NAMI-A elimination from the lungs is longer than for liver, kidney, and primary tumor. NAMI-A bound to collagen is active on tumor cells as shown in vitro by an invasion test, using a modified Boyden chamber and Matrigel, and it inhibits the matrix metallo-proteinases MMP-2 and MMP-9 at micromolar concentrations. The ruthenium drug NAMI-A inhibits the adhesion and migration of colorectal cancer cells. NAMI-A decreases α5β1 integrin expression and FAK auto-phosphorylation on Tyr 397. In vivo: The reference for NAMI-A is 35 mg/kg/day.

——

——

——

Angiogenesis

FAK

FAK

——

——

201653-76-1

458.18

C8H15Cl4N4ORuS

>98% (HPLC)

In Vitro:?H2O : 8.28 mg/mL (18.07 mM)

[H+].O=[S](C)(C)[Ru+3]([Cl-])([Cl-])([Cl-])([Cl-])[N]=1C=CNC1.N=1C=CNC1

——

(-20℃)

With Ice Pack

≥ 2 years